Who is the CEO of KolmarBNH?

According to the DART company overview, KolmarBNH's representative director is 이승화 (name as registered in Korean). The company was founded on 2014-04-22.

Where is KolmarBNH listed?

KolmarBNH trades on the Korea Exchange KOSDAQ market under the ticker 200130. Its fiscal year ends in December.

Does KolmarBNH pay a dividend?

Yes. For fiscal 2025, KolmarBNH paid a cash dividend of ₩75 per common share, a 0.5% yield as stated in its annual report. The prior year's dividend was ₩308.

Does KolmarBNH have any recent filing signals?

Signals detected automatically from DART filings and quarterly results: Dividend cut (dividend per share lower than, or dropped from, the prior year); Share pledge (a 5%+ holder reported a share pledge agreement (loan, extension or change) in the past 90 days); Major holder adding (a 5%+ shareholder reported raising its stake (30 days)). These are factual flags, not investment advice.

Which companies are in the same industry as KolmarBNH?

Under the Korean Standard Industrial Classification recorded on DART, KolmarBNH is grouped with 44 other listed companies in pharmaceutical ingredients. The most covered in Korean news over the past 30 days are Celltrion, Samsung Biologics and Medy-Tox.

KolmarBNH KRX:200130KOSDAQ

콜마비앤에이치 · Korean news coverage and regulatory filings, organized.

한국어

Articles, 24h0

Articles, 7 days3

DART filings, 7 days1

Articles tracked6since Sep 11

In Q2 2026, KolmarBNH reported revenue of ₩127bn, down 22.5% year on year, and operating profit of ₩10.2bn. KolmarBNH (콜마비앤에이치) appeared in 3 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Sep 29 with 3 articles. The most common catalyst was tech & capacity (1).

Filing signals Major holder adding Dividend cut Share pledge Screener

KolmarBNH quarterly results consolidated, KRW

Quarter	Revenue	YoY	Operating profit	Net income
Q2 2026	₩127bn	-22.5%	₩10.2bn margin 8.0%	₩6.9bn
Q1 2026	₩137bn	+0.1%	₩10.3bn margin 7.5%	₩22.4bn
Q4 2025 derived	₩122bn	-14.0%	₩2.6bn margin 2.2%	−₩37.0bn
Q3 2025	₩152bn	+3.0%	₩9.7bn margin 6.4%	₩6.2bn
Q2 2025	₩164bn	-1.1%	₩10.7bn margin 6.5%	₩6.7bn
Q1 2025	₩137bn	-14.7%	₩3.6bn margin 2.6%	₩1.4bn
Q4 2024 derived	₩142bn	-2.5%	₩3.2bn margin 2.3%	₩2.1bn
Q3 2024	₩147bn	+5.8%	₩4.1bn margin 2.8%	₩3.6bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

KolmarBNH top stories 2 weeks, by number of outlets

1
“콜마비앤에이치, 사업구조 정비 마무리…해외 고객사 확대 기대”
2 outlets · 3 articlesFirst report Sep 29 10:26 이데일리
2
콜마비앤에이치, 건기식 ODM 업계 최초 ‘Best HRD’ 인증 획득
1 outlets · 1 articlesFirst report Sep 18 10:39 매일일보Certification
3
콜마비앤에이치 '건기식 ODM' 전성시대 열까…내수·수출 쌍끌이 '활짝'
1 outlets · 1 articlesFirst report Sep 21 17:54 뉴스웍스

Latest KolmarBNH news Korean headlines

Sep 2910:26
“콜마비앤에이치, 사업구조 정비 마무리…해외 고객사 확대 기대”
이데일리
2 more on this story · 2 outlets
- “콜마비앤에이치, 사업구조 정비 마무리…해외 고객사 확대 기대”이데일리증권 · Sep 29 10:26
- “콜마비앤에이치, 사업구조 정비 마무리…해외 고객사 확대 기대”이데일리 · Sep 29 10:26
Sep 2117:54

콜마비앤에이치 '건기식 ODM' 전성시대 열까…내수·수출 쌍끌이 '활짝'
뉴스웍스
Sep 1810:39

Major콜마비앤에이치, 건기식 ODM 업계 최초 ‘Best HRD’ 인증 획득
매일일보Certification
Sep 1706:00

Exclusive中 ‘짝퉁 호주 영양제’ 파동… 한국콜마·광동제약 수출길 ‘불똥’
조선비즈Kwangdong Pharmaceutical Kolmar Korea

Articles per day 2 weeks

118

121

329

Company profile

CEO: 이승화
Industry: Pharmaceutical ingredients
Founded: 2014-04-22
Fiscal year-end: December
Head office: 세종특별자치시 전의면
Website: kolmarbnh.co.kr
Quotes & chart: Naver Securities (Korean)

From the DART company overview.

KolmarBNH dividends annual report

Korea dividend rankings

Year	Per share	Yield	Payout
FY2025	₩75	0.5%	–
FY2024	₩308	2.4%	48.3%
FY2023	₩308	1.8%	45.5%

KolmarBNH in the market close daily wrap

All wraps

Samsung, Hyundai Motor, Hana Financial Lead Busy Korea News DayWed, Sep 30

Major shareholders latest 5%+ report per holder

Korea 5% stake disclosures

콜마홀딩스54.84%

Each holder's most recent 5% ownership report on DART; names as filed in Korean.

Same industry Pharmaceutical ingredients

All in industry

Company	Latest quarter op. profit	Articles 30d
Celltrion	₩452bn	329
Samsung Biologics	₩586bn	96
Medy-Tox	₩4.8bn	67
ABL Bio	−₩16.8bn	62
Hugel	₩56.0bn	59
Orum Therapeutics	−₩15.4bn	35
ENCell	−₩4.7bn	27
SK Bioscience	−₩15.7bn	23

Compare KolmarBNH side by side with these companies

KolmarBNH DART filings

Sep 3016:37

5% ownership report 주식등의대량보유상황보고서(일반)
Ownership reports

Catalysts 2 weeks

Tech & capacity1

Mentioned alongside 2 weeks

No co-mentioned companies yet.

KolmarBNH FAQ

Who is the CEO of KolmarBNH?: According to the DART company overview, KolmarBNH's representative director is 이승화 (name as registered in Korean). The company was founded on 2014-04-22.
Where is KolmarBNH listed?: KolmarBNH trades on the Korea Exchange KOSDAQ market under the ticker 200130. Its fiscal year ends in December.
What were KolmarBNH's latest quarterly results?: In Q2 2026, KolmarBNH reported revenue of ₩127bn, down 22.5% year on year, and operating profit of ₩10.2bn. Figures come from reports filed on DART.
Does KolmarBNH pay a dividend?: Yes. For fiscal 2025, KolmarBNH paid a cash dividend of ₩75 per common share, a 0.5% yield as stated in its annual report. The prior year's dividend was ₩308.
Does KolmarBNH have any recent filing signals?: Signals detected automatically from DART filings and quarterly results: Dividend cut (dividend per share lower than, or dropped from, the prior year); Share pledge (a 5%+ holder reported a share pledge agreement (loan, extension or change) in the past 90 days); Major holder adding (a 5%+ shareholder reported raising its stake (30 days)). These are factual flags, not investment advice.
Which companies are in the same industry as KolmarBNH?: Under the Korean Standard Industrial Classification recorded on DART, KolmarBNH is grouped with 44 other listed companies in pharmaceutical ingredients. The most covered in Korean news over the past 30 days are Celltrion, Samsung Biologics and Medy-Tox.